MapLight Therapeutics
MapLight Therapeutics raises $372.5M Series D
Quick Facts
MapLight Therapeutics: Series D Funding Round
MapLight Therapeutics has successfully raised $372.5M in Series D funding.
Company Overview
Biopharma company developing medicines for brain disorders using novel drug discovery platform
Funding Details
The Series D round was led by Forbion, with participation from Goldman Sachs Alternatives.
Company Information
- Headquarters: Redwood City, CA
- Founded: 2018
- Employees: 150+
- Category: HealthTech
Investment
MapLight Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Forbion: Verified investor in Series D
- Goldman Sachs Alternatives: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
